Medicine recalls
|
| |
| Canada: Auro Pharma Losartan product recall |
| |
Health Canada announces that Auro Pharma Inc. is recalling the following losartan/ hydrochlorothiazide products from wholesalers, retailers and healthcare establishments due to presence of impurity (5-(4'-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-yl)-1H-tetrazole above the acceptable concentration limit in the affected lots. The affected products are:
- Auro-Losartan HCT 50mg/12.5mg (lot number: ACI5021007B, QX5019009-C, QX5019010-A, QX5019011-B, QX5019009-B)
- Auro-Losartan HCT 100mg/12.5mg (lot number: ACO1021003A, QY1018012-B, QY1018013-A, QY1018014-A, QY1018015-A, QY1019009-D, QY1018010-A, QY1018011-A, QY1018012-A, QY1019009-A)
- Auro-Losartan HCT 100mg/25mg (lot number: ACI1021007A, QX1019011-A, QX1019010-B, QX1019008-A, QX1019009-B, QX1019007-A)
Please refer to the following website in Health Canada for details:
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/../76627r-eng.php
In Hong Kong, the above products are not registered pharmaceutical products.
Ends/Friday, Oct 15, 2021
Issued at HKT 16:00
|
| |
